A comprehensive view of AIDS/HIV-Positive. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

JPMorgan rates Gilead as overweight, noting its emerging oncology business, and expecting HIV franchise to grow low single-digit CAGR though early 2030s; Biktarvy to remain dominant product with revenues growing from US$10.2B in 2022 to US$12.5B in 2025

Theratechnologies receives FDA approval for intravenous push mode delivery of its antiretroviral medication Trogarzo to treat HIV-1 in multidrug-resistant patients; intravenous push cuts dosing time from 15 minutes to 30 seconds

Merck to start new clinical trial to study lower dose of its experimental drug islatravir in combination with Pifeltro doravirine to treat HIV-1; Merck to end development of islatravir as HIV prevention drug

Gilead’s injectable lenacapavir HIV medication approved by European Commission for use every six months in combination with other antiretrovirals to treat adults with multidrug-resistant HIV; drug will be marketed as Sunlenca in Europe

Gilead Sciences announces collaboration with Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to address inequities in HIV care

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count